FibroGen to Report First Quarter 2025 Financial Results

Financial Results Announcement - FibroGen, Inc. will announce its first quarter 2025 financial results on May 12, 2025, after market close [1] - A conference call will be held on the same day at 5:00 PM Eastern Time to discuss the company's corporate and financial performance [1] Conference Call Details - The management team will host a conference call and webcast presentation to discuss financial results and provide a business update [2] - A live Q&A session will follow the presentation, and interested parties can access the live audio webcast [2] Company Overview - FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia [3] - Roxadustat is approved in multiple regions, including China, Europe, and Japan, for treating anemia in chronic kidney disease patients [3] - The company is evaluating a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. [3] - FG-3246, a first-in-class antibody-drug conjugate targeting CD46, is in development for metastatic castration-resistant prostate cancer [3] - The development program also includes FG-3180, a CD46-targeted PET biomarker [3]